In the news - 59 North

In the news

View the latest updates from the 59 North team and our clients below:

Mar

2026

Cereno Scientific Receives Approval to Initiate Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD

Mar

2026

One-carbon Therapeutics Signs Collaboration with Tempus to Advance Molecular Insights and Enable Precision Oncology Development of TH9619

Mar

2026

Targeting What Others Miss: How HaemaLogiX Is Tackling Multiple Myeloma’s Toughest Challenges

HaemaLogiX has been in the spotlight as it advances a differentiated approach to multiple myeloma, the world’s second‑largest blood cancer. In a recent episode of ...

-->

Mar

2026

etherna’s intratumoral mRNA/LNP platform advances to clinical testing in nonmelanoma skin cancer led by Almirall

Mar

2026

Why ‘Platform Or Perish’ Is Cell Therapy’s New Reality

Feb

2026

Measuring More of What Matters

Albus Health featured in The Pharma Navigator’s latest coverage on the future of clinical trial measuremen...

-->

Jan

2026

Reasons to be Cheerful in 2026

Nov

2025

AAVantgarde Closes $141 Million Series B for Stargardt Disease and Usher 1B Syndrome clinical development

Oct

2025

Rafiq Hasan discusses Complement Tx’s FDA IND clearance to advance CTx001 into Opti-GAIN Phase I/II Trial in GA secondary to AMD on BiotechTV

Oct

2025

Anti-CEA affibody for improved cancer detection and imaging

Oct

2025

For the first time the blind can see again

Oct

2025

ten23 health and Neumirna Therapeutics Team up to Develop RNA Therapy for Epilepsy

Oct

2025

Women’s Health high on the agenda at NLSDays

Oct

2025

Shahrzad Missaghi from Colorcon previews OSD trends for the Pharma Navigator

Oct

2025

Sweden and Switzerland strengthen ties

Oct

2025

BioXconomy report from Nordic Life Science Days on the culture driving success

Oct

2025

Dicot Announces Positive Results of Phase IIa study for new ED drug, LIB-01

Oct

2025

First Patients Enrolled in Diagnostic Phase 2 Imaging Study with Affibody’s PET Imaging Agent Tezatabep Matraxetan in Metastatic Breast Cancer

Oct

2025

Science Publishes Paper on PRIMA Vision Restoration Implant in NEJM

Oct

2025

Labiotech’s Jules Adam explores what the future holds for Swedish biotech

Oct

2025

GlobalData’s Rob Barrie reports on how Sweden is building one of Europe’s most dynamic biotech ecosystems.

Oct

2025

BD, ten23 health, and Partners to Demo full RFID Syringe Traceability at CPHI Frankfurt

Oct

2025

Cellevate to Announce Major Advances in Yield and Scalability of Viral Vaccine Production at WVC Europe with Global Launch of Cellevat3d® VAX Nanofiber Microcarriers

Oct

2025

Chris Spivey of PharmExec.com interviews ten23 Health CEO Hanns-Christan Mahler on understanding and managing risk in fill and finish manufacturing

Oct

2025

PharmNovo Secures CTA Approval in Spain initiating Phase IIa Trial of PN6047 to Treat Neuropathic Pain without Risk of Addiction

Oct

2025

Shani Alexander hears from AI Medical Technologies CEO Christoffer Ekstrom about how AI is revolutionising skin cancer detection

Oct

2025

Affibody Doses First Patient in Phase I Trial of ABY-271 for HER2+ Metastatic Breast Cancer

Oct

2025

NanoPhoria Announces Largest Ever Italian Series A Biotech Raise for HF Indication

Oct

2025

AAVantgarde Bio receives ODD and CTA for AAVB-039 to address Stargardt Disease

Sep

2025

Resitu Medical Receives 510(k) Marketing Authorization from US FDA for its Breast Biopsy Device

Sep

2025

Nanexa receives Japanese Patent Approval for Specific PharmaShell Structure

Sep

2025

Affibody Reports Positive 16-week Phase 3 Data of Izokibep in Hidradenitis Suppurativa Presented at EADV 2025

Sep

2025

Limula Announces Collaboration with Leading Cancer Centre to Improve Blood Products Processing for Stem Cell Transplantation

Sep

2025

CEO David Bejker explains how Affibody’s approach can solve many of the challenges facing radioligand therapy on BioBiz Buzz